Niowave Teams Up with Ratio Therapeutics for Actinium-225 Supply Agreement

Niowave and Ratio Therapeutics Join Forces for Cancer Treatment

In a significant move for the field of oncology, Niowave, Inc., a prominent manufacturer of medical radioisotopes, has entered into a supply agreement with Ratio Therapeutics, a forward-thinking pharmaceutical company dedicated to advancing cancer therapies. This strategic partnership, announced on June 16, 2026, aims to facilitate the development of targeted alpha therapies using Actinium-225, a highly valued alpha-emitting radioisotope.

The Promise of Actinium-225

Actinium-225 has garnered attention within the medical community for its potential to revolutionize cancer treatments. When linked with specific targeting molecules, this radioisotope delivers destructive alpha radiation directly to cancerous cells while sparing healthy tissues from damage. This capability is critical as the demand for precision-targeted therapies escalates.

The supply agreement is set to provide Ratio Therapeutics with a dependable source of cGMP-grade Actinium-225, essential for their ongoing clinical trials and future advancements in their programs. According to Matt Burba, President and Chief Commercial Officer of Niowave, their role as a reliable supplier highlights the importance of medical radioisotopes, particularly Actinium-225, in offering new hope to cancer patients.

Collaborative Efforts for Progress

Both Niowave and Ratio Therapeutics recognize that collaboration is key to advancing healthcare initiatives. John Babich, Ph.D., Chief Scientific Officer at Ratio, emphasized the importance of Niowave’s expertise and production capabilities. This partnership supports Ratio’s ongoing efforts to enhance its radiopharmaceutical pipeline, a vital aspect of their strategy to bring innovative cancer therapies to market.

Founded in 2005, Niowave has established itself as a leader in the production of medical isotopes. Based in Lansing, Michigan, the company operates superconducting electron linear accelerators and is dedicated to advancing radiochemistry for effective medical isotope production. Their mission to combat cancer via consistent and scalable supply reinforces their commitment to improving patient outcomes across various treatment modalities.

Ratio Therapeutics' Vision

Operating out of Boston, Ratio Therapeutics focuses on developing the next generation of precision radiopharmaceuticals specifically for solid tumors. The company prides itself on employing a multidisciplinary team of experts knowledgeable in radiopharmaceutical discovery and development. Ratio Therapeutics utilizes proprietary platforms, Trillium™ and Macropa™, to design heterobifunctional radiopharmaceuticals that enhance drug delivery and efficacy in targeting tumors.

Their state-of-the-art facility in Salt Lake City utilizes advanced manufacturing processes to ensure a consistent supply of quality radiopharmaceuticals, affirming their dedication to excellence in the pharmaceutical manufacturing sector.

Looking Ahead

The partnership between Niowave and Ratio Therapeutics marks a critical step in the journey to enhance cancer treatment options through targeted radiotherapy. As both companies continue their collaboration, the focus remains on fostering innovative solutions that not only advance clinical research but ultimately improve the lives of patients battling cancer.

For further information about Ratio’s product pipeline and the latest developments, visit their official website or follow their journey on social media platforms like Twitter and LinkedIn.

In summary, the agreement between Niowave and Ratio Therapeutics signifies a promising advancement in targeted alpha therapies, showcasing the critical role of reliable radioisotope supply in the fight against cancer.